Business Plan

/Tag:Business Plan

Approved the Bionaturis Group Capital Increase for a maximun of up to 579.129 new shares

The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

After the acquisition Bionaturis Group would have a global turnover over €8 Million in the year 2016, with an EBITDA’s operating margin about 30% and employing more than 60 workers, strengthening the Group’s industrial structure.

The Company carried out another capital increase operation last April 2014 for an amount worth of €3 Million with 76% of oversubscription.

Jerez, on June 2, 2015. The Alternative Equity Market (MAB) Governing Body has approved the Document of Capital Increase (Spanish DAM) presented by Bionaturis Group in order to formalize the capital increase operation authorized by its Board of Directors last May, 14 2015. This capital increase aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share.

If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a par value of €0,05 each one.

The new issued shares will trade in MAB as soon as possible […]

June 2nd, 2015|Blog english, Press Releases|Comments Off on Approved the Bionaturis Group Capital Increase for a maximun of up to 579.129 new shares

BIONATURIS clears the 2012 bar

The company increased its turnover figures and workforce in 2012.

The management team was able to smooth the impact of one time Stock Exchange listing expenses improving net result by 675 k € vs. the submitted original Business Plan.

In a year hit by a serious economic recession, Bionaturis (BNT-MAB) showed consistent growth, improving its results and creating jobs.

 The biotechnology company closed a successful year 2012 marked by important relevant facts like start trading at the Spanish Alternative Stock Market (MAB) in January and the launch in September of a new dermocosmetic business Line (BNT Dermocosmetics). Audited statements show an increase in its sales figures and total income vs. 2011, plus a considerable improvement in yearly net result of 675 k € compared to expectations presented at the Market in January 2012 (DIIM Business Plan).

 As Victor Infante, Bionaturis CEO, mentions, “If I would have to highlight something in 2012 above anything else I would choose our remarkable management capabilities. I refer to being able to smoothen the impact of starting trading in the Stock Market while putting together a new business line. It has been a great piece of a challenge. Our Strategic Plan for Growth has become a tangible reality”.

In its BNT PRODUCTS core business, Bionaturis keeps accomplishing important steps enriching its pipeline and patent portfolio. In this sense, the company has become a reference in oral fish vaccine development for aquaculture as a member of the European Targetfish International consortium and maintains fruitful activities towards licensing at least one vaccine development candidate during the period 2013-2015.

 Regarding its BNT-CDMO business line, the company´s R&D services division, the number of contracts with International corporations and private institutions have increased considerably in line with the pharmaceutical and veterinary […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.